Icosystem helps Eli Lilly save millions in drug development costs
Icosystem Corporation Press Release
Cambridge, MA - 26 February 2007

Lilly Sings A New Tune: Chorus Unit Brings High Efficiency Note To Early R&D

From The Pink Sheet, Vol.69/009, p.26
Printed by Patrick McAndrews, based on an interview by Mary Jo Laffler.

Lilly's independently operating Chorus drug development unit has created a means to mitigate the risk of drug development by conducting small-scale, targeted experiments separate from the larger R&D organization.

...One of the first steps in the Chorus experiment was to create a comprehensive computer model of a large R&D organization. Lilly contracted with Icosystem, a Boston-based strategy consulting company that analyzes complex organizational systems, and then used the model to "elucidate" various R&D processes.

...Chorus has been able to significantly cut both the time and cost of development through proof of concept. Compared to a standard 40 months and roughly $25 million, Bodick reported that Chorus has reached the "same amount of technical success in a year and a day with a total expenditure on the order of $2.7 million."

The full article is available from The Pink Sheet (subscription required), or by request to .

About Icosystem Corporation

Icosystem Corporation, a strategy consulting firm in Cambridge, Massachusetts, has emerged as a leader in the development of business applications for network theory and complexity science. Using the tools of complexity science and advanced computational techniques, Icosystem provides a highly flexible and cost-effective technology platform for exploring business problems and discovering or designing strategies that have significant impact. Icosystem's approach uses realistic models of complex business environments and evolutionary and distributed computational techniques to validate new business ventures or improve the performance of existing enterprises.